About the Company
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AYLA News
Ayala Corp. arm’s retail drugstore chain purchase reviewed on competition concern
THE Philippine Competition Commission (PCC) said it will conduct a “more detailed” review of the proposed acquisition by Ayala Corp.’s pharmaceutical arm of a Northern Luzon drugstore chain after the ...
PCC reviews Ayala unit’s acquisition of North Luzon drugstore chain
PCC reviews Ayala unit’s acquisition of North Luzon drugstore chain The Philippine Competition Commission (PCC) is conducting ...
Ayala’s St. Joseph Drug acquisition triggers intensive PCC review
THE PHILIPPINE Competition Commission (PCC) said it has started an in-depth review of Ayala Healthcare Holdings, Inc.’s (AC Health) proposed acquisition of a 49% stake in St. Joseph Drug. The ...
Global Desmoid Tumors Drug Pipeline Research Report 2024: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type
The "Desmoid Tumors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The report identifies approximately 12+ key players actively developing treatments for Desmoid ...
Concerns raised over Generika’s acquisition of North Luzon rival
The Philippine Competition Commission (PCC) said it launched an in-depth review of the proposed acquisition by the Generika ...
Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views
Across the recent three months, 4 analysts have shared their insights on HOOKIPA Pharma (NASDAQ:HOOK), expressing a variety ...
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hookipa Pharma (HOOK – Research Report), ...
MSD, AC Health agree to make cancer care products more affordable in the Philippines
Pharmaceutical company MSD and Healthway Medical Network (HMN), the hospital and clinic arm of Ayala Healthcare Holdings Inc.
AC Health eyes Cebu, Davao for potential M&As
AYALA Healthcare Holdings, Inc. (AC Health) is looking at the cities of Cebu and Davao for possible mergers and acquisitions (M&As) and investments as the company tries to expand its presence, its top ...
PHL’s first cancer specialty hospital, National Cancer Centre Singapore partner to strengthen cancer care
Ayala Healthcare Holdings, Inc. (AC Health) and its provider group, the Healthway Medical Network, recently announced a ...
Loading the latest forecasts...